RxDoctor Payments Data

Rodney Benjamin, MD

Pulmonary Disease · South Miami, FLNPI 1891758645

Payments from drug & device makers

$2,155in general payments, 2019–2025

Across 45 payments — averaging $47.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$987
  • Merck$238
  • GSK$173
  • Insmed, Inc.$116
  • Melinta Therapeutics, LLC$112
  • Verona Pharma, Inc.$88
  • plus $442 from 12 others

What the payments were for

  • Travel & lodging$93343%
  • Food & beverage$1,18455%
  • Education$392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,155 in reported general payments places this provider in the 40th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$231,804
Medicare patients
452
Services billed
2,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$71,050
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr48$55,232
Breo ElliptaFluticasone/Vilanterol39$26,146
SymbicortBudesonide/Formoterol Fumarate19$8,205
Arnuity ElliptaFluticasone Furoate22$7,246
Advair DiskusFluticasone Propion/Salmeterol27$6,907
Qvar RedihalerBeclomethasone Dipropionate22$5,757
Pulmicort FlexhalerBudesonide15$5,463
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,262
Fluticasone Propionate HfaFluticasone Propionate11$2,767
Wixela InhubFluticasone Propion/Salmeterol25$2,732
Fluticasone Propionate12$2,051
Ipratropium Bromide32$1,004
Azithromycin80$984
Albuterol Sulfate HfaAlbuterol Sulfate29$955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$173$159,674179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →